ラクトフェリン　2011

出版社： 日本医学館
著者：
発行日： 2011-11-30
分野： 基礎・関連科学  >  基礎医学関連科学一般
ISBN： 9784890447411
電子書籍版： 2011-11-30 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

5,500 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,750 円(税込)

購入する

商品紹介

2010年11月に開催された日本ラクトフェリン学会第４回学術集会の内容をまとめる。特別講演、シンポジウム“ラクトフェリンの抗微生物作用”、一般演題およびポスターセッションを収録。

目次

  • ラクトフェリン　2011

    ―目次―

    特別講演
    　ラクトフェリンの予防医学分野への活用

    シンポジウム
    “ラクトフェリンの抗微生物作用”
    　1．C型慢性肝炎に対するラクトフェリン・
    　　　ペグインターフェロン・リバビリン併用療法の効果
    　2．ウシラクトフェリンによるHTLV-1抗腫瘍効果
    　3．ウシラクトフェリン＋ラクトパーオキシターゼ
    　　　配合錠菓摂取による歯周炎への影響
    　4．大豆レシチンリポソーム化ラクトフェリンは
    　　　矯正的な歯の移動を阻害することなく
    　　　歯周組織の炎症ならびに組織破壊を抑制する
    　5．ラクトフェリンのアカントアメーバ臨床株に
    　　　おける抗アメーバ活性

    一般演題およびポスターセッション
    　1．スコティッシュ・フォールドの骨軟骨異形成症に
    　　　対するラクトフェリンの維持療法
    　2．ラクトフェリンはSmad3の発現とリン酸化を
    　　　促進することで、軟骨分化を調節する
    　3．非小細胞肺がん患者におけるゲムシタビン、
    　　　シスプラチン併用化学療法に対する
    　　　ウシラクトフェリンの有効性と安全千
    　4．ラクトフェリン＋ラクトパーオキシターゼ
    　　　配合錠菓の口臭抑制効果と唾液中細菌に対する影響
    　5．成熟脂肪細胞におけるラクトフェリンの脂肪分解促進作用
    　ほか

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

特別講演

P.5 掲載の参考文献
1) Sekine K, Ushida Y, Kuhara T et al.:Inhibition of initiation and early stage development of aberrant crypt foci and enhanced natural killer activity in male rats administered bovine lactoferrin concomitantly with azoxymethane. Cancer Lett 121:211-216, 1997.
 
2) Tsuda H, Sekine K, Nakamura J et al.:Inhibition of azoxymethane initiated colon tumor and aberrant crypt foci development in F344 rats. Advances in Lactoferrin Research. (ed Spik et al) . Plenum Press, New York. 1998, p 273-284.
 
3) Tsuda H, Kozu T, Iinuma G et al.:Cancer prevention by bovine lactoferrin:from animal studies to human trial. Biometals 23:399-409, 2010.
PubMed
4) Ono T, Morishita, S. Fujisaki C et al.:Effects of pepsin and trypsin on the anti-adipogenic action of lactoferrin against pre-adipocytes derived from rat mesenteric fat. Br J Nutr 105:200-211, 2011.
PubMed
5) Ono T, Murakoshi M, Suzuki N et al.:Potent anti-obesity effect of enteric-coated lactoferrin:Decrease in visceral fat accumulation in Japanese men and women with abdominal obesity after 8-week administration of enteric-coated lactoferrin tablets. Br J Nutr 104:1688-1695, 2010.
PubMed

シンポジウム

P.13 掲載の参考文献
1) Ikeda M, Sugiyama K, Tanaka T, Tanaka K, Kato N et al:Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. Biochem Biophys Res Commun 245:549-553, 1998.
PubMed
2) Ikeda M, Nozaki A, Tanaka K, Shimotohno K, Kato N et al.:Characterization of antiviral activity oflactoferrin against hepatitis C virus infection in human cuitured cells. Virus Res 66:51-63, 2000.
PubMed
3) Nozaki A, Ikeda M, Naganuma A, Tanaka K, Kato N et al.:Identification of lactoferrin-derived peptidepossessing binding activity to hepatitis C virus E2 envelope protein. J Biol Chem 278:10162-10173, 2003.
PubMed
4) Abe K, Nozaki A, Ikeda M, Tanaka K, Kato N et al:Tandem repeats of lactoferrin-derived anti-hepatitis Cvirus peptide enhance antiviral activity in cultured human hepatocytes. Microbiol Immunol 51:117-125, 2007.
 
5) Tanaka K, Ikeda M Nozaki A, Kato N, Tsuda H et al.:Lactoferrin inhibits hepatitis C virus viremia inpatients with chronic hepatitis C. Jpn J Cancer Res 90:367-371, 1999.
 
6) Okada S, Tanaka K, Sato T, Ueno H, Saito S et al.:Dose-response trial of lactoferrin in patients with chronic hepatitis C. Jpn J Cancer Res 93:1063-1069, 2002.
PubMed
7) Ueno H, Sato T, Yamamoto S, Tanaka K, Ohkawa S et al.:Randomized, double-blind, placebo-controlled trial of bovine lactoferrin in patients with chronichepatitis C. Cancer Sci 97:1105-1110, 2006.
 
8) Beleid R, Douglas D, Kneteman N, Kaur K:Helicalpeptides derived from lactoferrin bind hepatitis C virus envelope protein E2. Chem Biol Drug Des 72:436-443, 2008.
 
P.20 掲載の参考文献
1) Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H;Adult T-cell leukemia;clinical and hematologic features of 16 cases. Blood 50(3) ;481-492, 1977.
PubMed
2) Hinuma Y, Nagata K, Hanaoka M. Nakai M, Matsumoto T et al. ;Adult T-cell leukemia;antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 78 (10) ;6476-6480, 1981.
 
3) Watanabe T;HTLV-1-associated diseases. Int J Hematol 66(3) ;257-278, 1997.
PubMed
4) Kinoshita K, Amagasaki T, Hino S, Doi H, Yamanouchi K et al. ;Milk-borne transmission of HTLV-I from carrier mothers to their children. Jpn J Cancer Res 78(7) ;674-680, 1987.
PubMed
5) Kawase K, Katamine S, Moriuchi R, Miyamoto T, Kubota K et ai. ;Maternal transmission of HTLV-1 Other than through brest milk;discrepancy between the polymerase chain reaction positivity of cord blood sample for HTLV-1 and the subsequent seropositivity of individuals. Jpn J Cancer Res 83 (9) ;968-977, 1992.
 
6) Sugiyama H, Doi H, Yamaguchi K, Tsuji Y, Miyamoto T et al. ;Significance of postnatal mother-to-child transmission of human T-lymphotropic virus type-I on the development of adult T-cell leukemia/lymphoma. J Med Virol 20;253-260, 1986.
PubMed
7) 田中正和, 鄭 真美, 小西智子, 河津祐介, 長谷川 翔・他:ラクトフェリンによるHTLV-1感染抑制効果. ラクトフェリン2009. 日本医学館, 2009, p55-62.
 
8) Furuta RA, Sugiura K, Kawakita S, Inada T, Ikehara S et al. ;Mouse model for the equilibration interaction between the host immune system and human T-cell leukemia virus type 1 gene expression. J Virol 76(6) ;2703-2713, 2002.
PubMed
9) Etoh K, Yamaguchi K, Tokudome S, Watanabe T, Okayama A et al;Rapid quantification of HTLV-I provirus load;detection of monoclonal proliferation of HTLV-1-infected cells among blood donors. Int J Cancer 81(6) ;859-864, 1999.
PubMed
10) Kamihira S, Sohda H, Atogami S, Toriya K, Yamada Y et al. ;Phenotypic diversity and prognosis of adult T-cell leukemia. Leuk Res 16(5) ;435-441, 1992.
PubMed
11) Makino M, Wakamatsu S, Shimokubo S, Arima N, Baba M;Production of functionally deficicnt dendritic cells from HTLV-1-infected monocvtes; implications for the dendritic cell defect in adult T cell leukemia. Virology 274(1) ;140-148, 2000.
PubMed
12) Jones KS, Petrow-Sadowski C, Huang YK, Bertolctte DC, Ruscetti FW;Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4(+) T cells. Nat Med 14(4) ;429-436, 2008.
PubMed
13) Spadaro M, Caorsi C, Ccruti P, Varadhachary A, Forni G et al. ;Lactoferrin. a major defense protein of innate immunity. is a novel maturation factor for human dendritic cells. FASEB J 22(8) ;2747-2757, 2008.
 
14) Onishi Y, Fchervari Z, Yamaguchi T, Sakaguchi S;Foxp3+natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci USA 105(29) ;10113-10118, 2008.
 
15) Marski M Kandula S, Turner JR, Abraharri C;CD18 is required for optimal development and function of CD4+CD25+ T regulatory cells. J Immunol 175 (12) ;7889-7897, 2005.
 
16) Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A et al. ;A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma;Japan Clinical Oncology Group Study 9303. Br J Haematol 113(2) ;375-382, 2001.
 
P.25 掲載の参考文献
1) Levay PF Viljoen M:Lactoferrin. A general review. Haematologica 80:252-267, 1995.
PubMed
2) Thomas EL, Bozeman PM, Learn DB, Lactoperoxidase:structure and catalytic properties. Peroxidases in Chemistry and Biology. (ed. Everse J, Everse KE, Grisham MB) . CRC, Boca Raton. 1991. p123-142.
 
3) Aguilera O, Andres MT, Heath J, Fierro JF, Douglas CWI:Evaluation of the antimicrobial effect oflactoferrin on Porphyromonas gingivalis, Prevotella intermedia and Prevotella nigrescens. FEMS ImmunolMed Microbiol 21:29-36, 1998.
 
4) Shi Y, Kong W, Nakayama K:Human lactoferrin binds and removes the hemoglobin receptor proteinof thc periodontoPathogen Porphyromonas gingivalis. J Biol Chem 275:30002-30008, 2000.
 
5) Ihalin R, Loimaranta V, Lenander-Lumikari M, Tenovuo J:The sensitivity of Porphyromonas gingivalis and Fusobacterium nucleatum to different(pseudo) halide-peroxidase combinations compared with mutans streptococci, J Med Microbiol 50:42-48, 2001.
PubMed
6) 近藤一郎, 小林哲夫, 若林裕之, 山内恒治, 岩附慧二. 吉江弘正:歯周炎患者におけるウシラクトフェリン経口投与の影響. 日歯保存誌 51:281-291, 2008.
Medical*Online
7) Silness J, Loe H:Periodontal discase in pregnancy. II. Correlation between oral hygiene and and periodontal condition. Acta Odontol Scand 22:121-135, 1964.
 
8) Loe H, Silness J:Periodontal discase in pregnancy. I. Prevalence and severity. Acta Odontol Scand 21:533-551, 1963.
 
9) O'Leary TJ, Drake RB, Naylor JE:The plaque control record. J Periodontol 43:38, 1972.
 
10) Tadokoro K, Yamaguchi T, Kawamura K, Shimizu H, Egashira T et al.:Rapid quantification of periodontitis-related bacteria usinganovel modification of Invader PLUS technologies. Microbiol Res 165:43-49, 2010.
PubMed
11) Wakabayashi H, Yamauchi K, Kobayashi T, Yaeshima K, Iwatsuki K et al.:Inhibitory effect of lactoferrin on growth and biofilm formation of Porphyromonas gingivalis and Prevotella intermedia. Antimicrob Agents Chemother 53:3308-3316, 2009.
 
12) Watts T:Periodontal treatment and glycemic control in diabetic patients:the problem of a possible Hawthorne effecc J Dent Res 85:294-295, 2006.
 
P.33 掲載の参考文献
1) 加藤 煕:臨床家のための歯周病患者の局所矯正治療. 医歯薬出版, 2007, p37-40.
 
2) Dersot JM:Plaque controL a key element of successful orthodontics. Ortho Fr 81:33-39, 2010.
 
3) Quock RL, Warren-Morris DP:Fluoride varnish:the top choice for professionally applied fluoride. Tex Dent J 127:749-759, 2010.
PubMed
4) 可児靖夫, 可児徳子, 飯野新太郎, 磯崎篤則, 高橋美次:フッ素含有洗口液による齲蝕予防法. 口衛学誌 30:98-103, 1980.
 
5) Atassi F, Awartani F:Oral hygiene status among orthodontic patients. J Contemp Dent Pract 11:25-32, 2010.
 
6) Zaric S. Shelburne C, Darvcau R, Quinn DJ, Weldon S et al.:Impaired immune tolerance to porphyromonas gingivalis lipopolysaccharide promotes neutrophil migration and decreased apoptosis. Infect Immun 78:4151-4156, 2010.
 
7) Nociti FH, Foster BL, Barros SP, Darveau RP, Somerman MJ:Cementoblast gene expression is regulated by porphyromonas gingivalis lipopolysaccharide partially via toll-like receptor-4/MD-2. J Dent Res 83:602-607, 2004,
PubMed
8) Tomomatsu N, Aoki K, Alles N, Soysa NS, Hussain A et al:LPS-induced inhibition of osteogenesis is TNF alpha dependent in a murine tooth extraction model. J Bone Miner Res 24:1770-1781, 2009.
 
9) McFarllane CG, Reynolds JJ, Meikle MC:The release of interleukin-1β, tumor necrosis factor-α and interferon-γ by cultured peripheral blood mononuclear cells from patients with periodontitis. J periodonta Res 25:207-214, 1990.
 
10) Lindemann RA, Economou JS, Rothermel H:Production of interleukin-1 and tumor necrosis factor by human pcripheralmonocytes activated by periodontal bacteria and extracted lipopolysaccharides. J DentRes 67:1131-1135, 1988.
 
11) Ishikado A, Imanaka H, Takeuchi T, Harada E, Makino T:Liposomalization of lactoferrin enhanced it's anti-inflammatory effects via oral administration. Biol Pharm Bull 28:1717-1721, 2005.
 
12) Orla M:Antiinflammatory activities of lactoferrin. J Am Coll Nutr 20:389-395, 2001.
 
13) Bezwoda WR, Mansoor N:Lactoferrin from human breast milk and from nutrophil granulocytes. Comparative studies of isolation, quantitation, characterization and iron binding properties. Biomed Chromatogr 3:121-126, 1989.
 
14) Moguilevsky N, Masson PL, Courtoy PJ:Lactoferrin uptake and iron processing into macrophages:a study in familial haemochromatosis. Br J Haematol 66:129-136, 1987.
PubMed
15) Banyard MR, Maeda K:The isolation and identification of lactoferrin from bovine tears. Aust J Exp Bio Med Sci 56:481-492, 1978.
 
16) Guillen C, McInners IB, Vaughan D, Speekenbrink AB, Brock JH:The effects of local administration of lactoferrin on inflammation in murine autoimmune and infectious arthritis. Arthritis Rheum 43:2073-2080, 2000.
 
17) Yamaguchi M, Matsuura M, Kobayashi K, Sasaki H, Yajima T et al.:Lactoferrin protects against development of hepatitis caused by sensitization of Kupffer cells by lipopolysaccharide. Clin Diagn Lab Immunol 8:1234-1239, 2001.
PubMed
18) Kimber I, Cumberbatch M, Dearman RJ, Headon DR, Bhushan M et al.:Lactoferrin:influences on langerhans cells, epidermal cytokines, and cutaneous inflammation. Biochem Cell Biol 80:103-107, 2002.
PubMed
19) Hayashida K, Kaneko T, Takeuchi T, Shimizu H, Ando K et al.:Oral administration of lactoferrin inhibits inflammation and nociception in rat adjuvant-induced arthritis. J Vet Med Sci 66:149-154, 2004.
PubMed
20) 川添亜希, 宮内睦美, 山野栄三, 石角 篤, 田中栄二・他:大豆レシチンによるリポソーム化ラクトフェリン経口投与がリポポリサッカライド誘導歯周組織破壊に及ぼす抑制効果. ラクトフェリン2009. 日本医学館, 2009, p79-83.
 
21) Yamano E, Miyauchi M, Furusyo H, Kawazoe A, Ishikado A et al.:Inhibitory effects of orally administrated liposomal bovine lactoferrin on the LPS-induced osteoclastogencsis. Lab Invest 90:1236-1246, 2010.
PubMed
22) Matsuzaki H, Kobayashi H, Yagyu T, Wakahara K, Kondo T et al:Bikunin inhibits lipopolysaccharide-induced tumor necrosis factor alpha induction in macrophages. Clin Diagn Lab Immunol 11:1140-1147, 2004.
PubMed
23) Miyauchi M, Sato S, Kitagawa S, Hiraoka M, Kudo Y et al.:Cytokine expression in rat molar gingival periodontal tissues after topical application of lipopolysaccharide. Histochem Cell Biol 116:57-62, 2001.
PubMed
24) Sanuki R, Shionome C, Kuwabara A, Mitsui N, Koyama Y et al:Compressive force induces osteoclast differentiation via prostaglandin E(2) production in MC3T3-E1 cells. Colmect Tissue Res 51:150-158, 2010.
PubMed
25) Grieve WG III, Johnson GK, Moore RN, Rcinhardt RA, DuBois LM:Prostaglandin E(PGE) and interleukin-1 beta(IL-1 beta) levels in gingival crevicular fluid during human orthodontic tooth movement. Am J Orthod Dentofacial Orthop 105:369-374, 1994.
 
P.40 掲載の参考文献
1) 石井圭一:総論. アメーバの定義. アメーバ図鑑. (堀上英紀, 木原 章・編) , 金原出版, 1999, p13-14.
 
2) Verani JR, Lorick SA, Yoder JS, Beach MJ, Braden CR et al.:National outbreak of Acanthamzoeba keratitis associated with use of a contact lens solution, United States. Emerging Infect Dis 15:1236-1242, 2009.
PubMed
3) Matsue M, Tomita S, Nyui S, Matsuyama J, Kiyosawa I:Suppressive effects of lactoferrin on bleomycin-dependent DNA damage by the iron ion and ascorbate. Biosci Biotechnoi Biochem 58:67-71, 1994.
 
4) 冨田信一, 魚谷孝之, 高野真未, 脇野英明, 山崎亮祐, 新本洋士, 東岸和明:ラクトフェリンによるHartmannella細胞の増殖抑制作用. ラクトフェリン 2009. (第3回ラクトフェリンフォーラム実行委員会・編) , 日本医学館. 2009. p137-141.
 
5) 冨田信一, 魚谷孝之, 松山 惇:ラクトフェリンのBifidobacterium菌体への結合性と増殖性との関係. ラクトフェリン2007. (第2回ラクトフェリンフォーラム実行委員会・編) . 日本医学館. 2007. p141-147.
 
6) 福田昌彦:コンタクトレンズ関連角膜感染症の実体と疫学. 日本の眼科 80:693-698, 2009.
 
7) 中村さや花, 外園千恵, 稲富 勉, 上川真由美, 塩田 恒三, 木下 茂:多数のアメーバと細菌がコンタクトレンズに付着していたアカントアメーバ角膜炎の2例. あたらしい眼科 27:85-89, 2010.
 

一般演題およびポスターセッション

P.46 掲載の参考文献
1) Wasthuber J:History of domestic cats and cat breeds. Pratt, Editor. Feline Husbandry Diseases and Management in the Multi-cat Environment. American Veterinary Publications, Goleta, 1991, p12-14.
 
2) Robinson R, Pedersen NC:Normal genetics, genetic disorders, developmental anomalies and breeding programs. Pratt, Editor, Feline Husbandry Diseases and Management in the Multi-cat Environment. American Veterinary Publications, Goleta, 1991, p75-76.
 
3) Jackson O F:Congenital bone lesions in cats with folded ears. Bull Fel Advis Bur 14:2-4, 1975.
 
4) Malik R, Allan GS, Howlett CR, Thompson DE, James G et al:Osteochondrodys plasia in Scottish Fold cats. Aust Vet J 77:85-92. 1999.
 
5) Chang J, Jung J, Oh S, Lee S, Kim G et al.:Osteochondrodysplasia in three Scottish Fold cats. J Vet Sci 8:307-309, 2007.
 
6) Hubler M, Volkert M, Kaser-Hotz B, Arnold S:Palliative irradiation of Scottish Fold osteochondro-dysplasia. Vet Radiol Ultrasound 45:582-585, 2004.
 
7) Hayashida K, Takeuchi T, Shimizu H, Ando K, Harada E:Novel central function of milk-derived lactoferrin on anti-nociception mediated by the u-opioid receptor. Brain Res 965:239-245, 2003.
 
8) Hayashida K, Takeuchi T, Shimizu H, Ando K, Harada E:Lactoferrin enhances opioid-mediated analgesia via nitric oxide in the rat spinal cord. Am J physiol 285:R306-R312, 2003.
 
9) Hayashida K, Kaneko T, Takeuchi T, Shimizu H, Ando K et al.:Oral administration of lactoferrin inhibits inflammation and nociception in rat adjuvant-induced arthritis. J Vet Med Sci 66:149-154, 2004.
PubMed
10) Naot D, Grey A, Reid L Cornish J:Lactoferrin-a novel bone growth factor. Clin Med Res 3:93-101, 2005.
 
11) Guo HY, Jiang L, Ibrahim SA, Zhang L, Zhang H, et al.:Orally administered lactoferrin preserves bone mass and microarchitecture in ovariectomized rats. J Nutr 139:958-964, 2009.
 
P.53 掲載の参考文献
1) 河村直洋, 鄭 雄一:骨の成長を司るシグナル. 骨研究がわかるシグナル研究から広がる骨代謝と生体制御のクロストーク. (高柳広・編) , 羊土社. 2005, p32-41.
 
2) 開 祐司:軟骨再生の分子機構と治療への展開. 最新医学 103:2843-2849, 1999.
 
3) 松山博昭, 森田如一, 小野愛子, 芹澤 篤, 川上 浩:MBP(乳塩基性タンパク質)の骨強化作用. ミルクサイエンス 54(3) :133-136. 2005.
 
4) Amini AA, Nair LS:Lactoferrin:a biologically active molecule for bone regeneration. Curr Med Chem 18(8) :1220-1229, 2011.
PubMed
5) Takayama Y. Mizumachi K:Inhibitory effect of lactoferrin on hypertrophic differentiation of ATDC5 mouse chondroprogenitor cells. Biometals 23:477-484, 2010.
PubMed
6) Yagi M, Suzuki N, Takayama T, Arisue M, Kodama T et al:Effects of lactoferrin on the differentiation of pluripotent mesenchymal cells. Cell Biol Int 33(3) :283-289. 2009.
PubMed
7) Brandl N, Zemann A. Kaupe I. Marlovits S, Huettinger P:Signal transduction and metabolism in chondrocvtes is modulated by lactoferrin. Osteoarthritis Cartilage 18:117-125, 2010.
PubMed
8) Zemann N, Klein P. Wetzel E, Huettinger F, Huettinger M:Lactoferrin induces growth arrest and nuclear accumulation of Smad-2 in HeLa cells. Biochimie 92:880-884, 2010.
PubMed
P.57 掲載の参考文献
1) Non-small Cell Lung Cancer Collaborative Group:Chemotherapy in non-small cell lung cancer:A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311:899-909, 1995.
 
2) Marino P, Pampallona S, Preatoni A, Cantoni A, Invernizzi F et al.:Chemotherapy vs supportive care in advanced non-small-cell lung cancer:results of a meta-analysis of the literature. Chest 106:861-865, 1994.
PubMed
3) Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH et al.:Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer:a Southwest Oncology Group study. J Clin Oncol 16:2459-2465. 1998.
 
4) Yana T, Takada M, Origasa H, Ijima T, Yamamoto N et al.:New chemotherapy agent plus platinum for advanced non-small-cell lung cancer:a meta-analysis. Proc Am Soc Clin Oncol 21:328a, 2002.
 
5) Sandler A, Nemunaitis J, Dehnam C, Cormier Y, J vo Pawel et al.:Phase III study of cisplatin with or without gemcitabine in patients with advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 17:A1747, 1998.
 
6) Schiller JH, Harrington D, Belani CP, Langer C, Sandler A et al.:Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346(2) :92-98, 2002.
PubMed
7) Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R et al.:Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer:a meta-analysis of survival outcomes. Lung Cancer 47:69-80, 2005.
PubMed
8) 栗田雄三, 横山 晶, 松井 薫, 原 信之, 中井祐之・ 他:非小細胞肺癌に対するGemcitabine Hydrochloride (LY 188011)とCisplatinとの併用第1相試験. 癌と化学療法 26(7) :898-907, 1999.
Medical*Online
9) Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K et al:Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer:Four-Arm Cooperative Study in Japan. Ann Oncol 18(2) :317-323, 2007.
PubMed
10) Iijima H, Tomizawa Y, Iwasaki Y, Sato K, Sunaga N et al.:Genetic and epigenetic inactivation of LTF gene at 3P21. 3 in lung cancer. Int J Cancer 118(4) :79 7-801, 2006.
 
11) Matsuda Y, Saoo K, Hosokawa K, Yamakawa K, Yokohira M et al.:Post-initiation chemopreventive effcctsofdietary bovine lactoferrin on 4-(methylnitrosamino)-1-(3-pyridyl)-1 butanone-induced lung tumorigenesis in female A/J mice. Cancer Lett 246(1-2) :41-46, 2007.
 
12) Petrak K, Varadhachary A, NSCLC Clinical Investigator Group, Yankec E, Wang Y et al:Double-blind, placebo controlled trial of oral talactoferrin in combination therapy for first-line non-small cell lung cancer. 7th International Conference on Lactoferrin:Structure, Function and Applications, 2005.
 
13) Scagliotti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C et al.:Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20(21) :4285-4291, 2002.
PubMed
14) Smit EF, van Meerbeeck JPAM, Lianes P, Debruyne C, Legrand C et al.:Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer. J Clin Oncol 21(21) :3909-39. 17, 2003.
 
15) Alberola V, Camps C. Provencio M, Isla D, Rosell R et al:Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell-lung cancer. J Clin Oncol 21(17) :3207-3213, 2003.
PubMed
16) 高橋清美, 角田 出:ラクトフェリンによる化学療法剤の副作用の軽減. ラクトフェリン2007. 日本医学館, 2007, p226-230.
 
P.63 掲載の参考文献
1) Yaegaki K:Halitosis. (ed. Johnson LR) . Encyclopedia of Gastroenterology, vol.2. Elsevier, San Diego, 2003, p265-266.
 
2) Yaegaki K, Coil JM, Kamemizu T, Miyazaki H:Tongue brushing and mouth rinsing as basic treatment measures for halitosis. Int Dent J 52:192-196. 2002.
PubMed
3) 硫化水素-環境汚染物質の生体への影響(15)-. National Research Council・編, 東京化学同人. 1982. P23.
 
4) Ng W, Tonzetich J:Effect of hydrogen sulfide and methyl mercaptan on the permeability of oral mucosa. J Dent Res 63:994-997, 1984.
PubMed
5) Persson S, Edlund MB, Claesson R. Carlsson J:The formation of hydrogen sulfide and methyl mercaptan bv oral bacteria. Oral Microbiol Immunol 5:195-201. 1990.
 
6) Johnson PW, Yaegaki K, Tonzetich J:Effect of volatile thiol compounds on protcin metabolism by human gingival fibroblasts. J periodontal Res 27:553-561. 1992.
PubMed
7) Johnson PW, Yaegaki K, Tonzetich J:Effect of methyl mercaptan on synthesis and degradation of collagen. J Periodontal Res 31:323-329, 1996.
 
8) Imai T, Ii H, Yaegaki K, Murata T, Sato T, Kamoda T:Oral malodorous compound inhibits osteoblast proliferation. J Periodontol 80:2028-2034, 2009.
PubMed
9) Irie K, Ekuni D, Yamamoto T, Morita M, Yaegaki K et al.:A single application of hydrogen sulfide induces a transient osteoclast differentiation with RANKL expression in the rat model. Arch Oral Biol 54:723-729, 2009.
PubMed
10) Yaegaki K. Qian W, Murata T, Imai T, Sato T et al.:Oral malodorous compound causes apoptosis and genomic DNA damage in human gingival fibroblasts. J Periodontal Res 43:391-399, 2008.
PubMed
11) Fujimura M, Calenic B, Yaegaki K, Murata T, Ii H et al:Oral malodorouscompoundactivates mitochondrial pathway inducing apoptosis in human gingival fibroblasts. Clin Oral Invest 14:367-373. 2010.
 
12) Calenic B, Yaegaki K, Murata T, Imai T, Aoyama I et al:Oral malodorous compound triggers mitochondrial-dependent apoptosis and causes gcnomic DNA damage in human gingival epithelial cells. J Periodontal Res 45:31-37, 2010.
PubMed
13) Yaegaki K:Unangenehm riechende Substanzen im Mundraum:Grunde fur Parodontitis und Krebs. PROPHYLAXEdialog Sonderausgabe Halitosis 22-25, 2009.
 
14) Calenic B, Yaegaki K, Kozhuharova A, Imai T:Oral malodorous compound causes oxidative stress and p53-mediated programmcd cell death in keratinocyte stem cells. J Periodontol 81:1317-1323, 2010.
PubMed
15) Ii H, Imai T, Yaegaki K, Irie K, Ekuni D et al.:Oral malodorous compound inducesosteoclast differentiation without receptor activator of nuclear factor xB ligand. J Periodontoi 81:1691-1697, 2010.
 
16) Thomas EL, Bozeman PM, Learn DB:Lactoperoxidase:structure and catalytic properties. (eds. Everse J, Everse KE, Grisham MB) , Peroxidases in chemistry and biology, vol.1. CRC, Boca Raton, 1991, p123-142.
 
17) Arnold RR, Russell JE, Champion WJ, Brewer M, Gauthier JJ:Bactericidal activity of human lactoferrin:differentiation from the stasis of iron deprivation. Infect Immun 35:792-799, 1882.
 
18) Thomas EL, Milligan TW, Joyner RE, Jefferson MM:Antibacterial activity of hydrogen peroxide and the lactoperoxidase-hydrogen peroxide-thiocyanate system against oral streptococci. Infect Immun 62:529-535, 1994.
PubMed
19) Ihalin R, Loimaranta V, Lenander-Lumikari M, Tenovuo J:The sensitivity of Porphyromonas gingivalis and Fusobacterium nucleatum to different (pseudo) halide-peroxidase combinations compared with mutans streptococci. J Med Microbiol 50:42-48. 2001.
PubMed
20) Shin K, Yaegaki K, Murata T, Ii H, Tanaka T et al.:Effects of a composition containing lactoferrin and lactoperoxidase on oral malodor and salivary bacteria:a randomized, double-blind, crossover, placebo-controlled clinical trial. Clin Oral Invest 15:485-493, 2011.
 
21) Murata T, Yamaga T. Iida T, Miyazaki H, Yaegaki K:Classification and examination of halitosis. Int Dent J 52:181-186, 2002.
PubMed
22) Wakabayashi H, Yamauchi K, Kobayashi T, Yaeshima T, Iwatsuki K, et al.:Inhibitory effects of lactoferrin on growth and biofilm formation of Porphyromonas gingivalis and Prevotella intermedia. Antimicrob Agents Chemother 53:3308-3316, 2009.
PubMed
23) Kondo I, Kobayashi T, Wakabayashi H, Yamauchi K, Iwatsuki K et al.:Effects of oral administration of bovine lactoferrin on periodontitis patients. Jpn J Conserv Dent 51:281-291, 2008.
 
24) Shin K, Horigome A, Wakabayashi H, Yamauchi K, Yaeshima T et al.:In vitro and in vivo effects of a composition containing lactoperoxidase on oral bacteria and breath odor. J Breath Res 2:017014 (E-pub) , 2008.
 
P.68 掲載の参考文献
1) 鈴木苗穂, 木川博光, 小野知二, 関谷大輔, 村越倫明・他:ラクトフェリンによる歯周病予防効果～ヒト由来歯肉線維芽細胞に対する影響. ラクトフェリン 2007. 第2回ラクトフェリンフォーラム実行委員会編集, 日本医学館. 2007. p68-72.
 
2) 小野知二, 村越倫明:ラクトフェリンにより脂質代謝の制御. 化学と生物 49:15-21, 2011.
 
3) Takeuchi T, Shimizu H, Ando K, Harada E:Bovine lactoferrin reduces plasma triacylglycerol and NEFAaccompanied by decreased hepatic cholesterol and triacylglycerol contents in rodents. Br J Nutr Apr 91(4) :533-538, 2004.
PubMed
4) 鈴木苗穂:2007年度農芸化学会. 2007年度栄養食糧学会
 
5) Ono T, Murakoshi M, Suzuki N, Iida N, Ohdera M, et al:Potent arlti-obesity effect of enteric-coated lactoferrin:decrease in visceral fat accumulation in Japanese men and women with abdominal obesity after 8 week administration of enteric-coated lactoferrin tablets. Br J Nutr 104:1688-1695, 2010.
PubMed
6) Ono T, Morishita S, Fujisaki C, Ohdera M, Murakoshi Met al:Effects of pepsin and trypsin on the anti-adipogenic action of lactoferrin against preadipocytes derived from rat mesenteric fat. Br. J. Nutr. 105:200-211, 2011
 
7) Wakabayashl H, Takase M, Tomita M.:Lactoferricin derived from milk protein lactoferrin. Curr Pharm Des 9:1277-1287. 2003.
PubMed
P.77 掲載の参考文献
1) Alexander DA, Iigo M, Yamauchi K, Suzui M, Tsuda H:Lactoferrin Containing Fluids:An Alternative View. Biochemistry and Cell Biology(Submited).
 
2) Ando K et al.:Human lactoferrin activates NFkappaB through the Toll-like receptor 4 pathway while it interferes with the lipopolysaccharidestimulatcd TLR4 signaling. Febs J 277:2051-2066, 2010.
PubMed
3) Mirza S et al.:Serine protease PrtA from Streptococcus pneumoniac plays a role in the killing of S. pneumoniae by apolactoferrin. Infect Immun 79:2440-2450, 2011.
 
4) Daidone I et al.:Conformational study of bovine lactoferricin in membrane-micking conditions by molecular dynamics simulation and circular dichroism. Biometals 24:259-268, 2011.
PubMed
5) Farnaud S, Patel A, Odell EW, Evans RW:Variation in antimicrobial activity of lactoferricin-derived peptides explained by structure modelling. FEMS Microbiol Lett 238:221-226, 2004.
PubMed
6) Gifford JL, Hunter HN Vogel HJ:Lactoferricin:a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immumological properties. Cell Mol Life Sci 62:2588-2598, 2005.
 
7) Hunter HN, Demcoe AR, Jenssen H, Guttebcrg TJ, Vogel HJ:Human lactoferricin is partially folded in aqueous solution and is better stabilized in a membrane mimetic solvent. Antimicrob Agents Chemother 49:3387-3395, 2005.
 
8) Hwang PM, Zhou N, Shan X, Arrowsmith CH Vogel HJ:Three-dimensional solution structure of lactoferricin B, an antimicrobial peptide derived from bovine lactoferrin. Biochemistry 37:4288-4298, 1998.
PubMed
9) Iigo M et al:Anticarcinogencsis pathways activated by bovine lactoferrin in the murine small intestine. Biochimie gl:86-101, 2009.
 
10) Wang WP et al.:Activation of intestinal mucosal immunity in tumor-bearing mice by lactoferrin. Jpn J Cancer Res 91:1022-1027, 2000.
PubMed
11) Kozu T et al.:Effect of orally administered bovine lactoferrin on the growth of adenomatous colorectal polyps in a randomized, placebo-controlled clinical trial. Cancer Prev Res(Phila) 2:975-983, 2009.
 
12) Tsuda H et al.:Cancer prevention by bovine lactoferrin:from animal studies to human trial. Biometals 23:399-409, 2010.
PubMed
13) Kudo S et al.:Diagnosis of colorectal tumorous lesions by magnifying endoscopy. Gastrointest Endosc 44:8-14, 1996.
PubMed
14) Kyzer SD, Gordon PH, Wang E:Immunohistochemical analysis of statin in colorectal adenocarcinoina, polyps, and normal mucosa. Dis Colon Rectum 39:546-551, 1996.
PubMed
15) Rostom A et al.:Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer:a systematic review prepared for the U. S. Preventive Services Task Force. Ann Intern Med 146:376-389, 2007.
 
16) Fujita K. Matsuda E, Sekine K, Iigo M, Tsuda H:Lactoferrin modifies apoptosismrelated gene expression in the colon of the azoxymethane-treated rat. Cancer Lett 213:21-29, 2004.
PubMed
17) Fujita K, Matsuda E, Sekine K, Iigo M, Tsuda H:Lactoferrin enhances Fas expression and apoptosis in the colon mucosa of azoxymethane-treated rats. Carcinogenesis 25:1961-1966, 2004.
PubMed
18) Li C et al.:IFNalpha induces Fas expression and apoptosis in hedgehog pathway activated BCC cells throLigh inhibiting Ras-Erk signaling. Oncogene 23:1608-1617, 2004.
PubMed
19) Freitas M, Porto G, Lima JL, Fernandes E:Isolation and activation of human neutrophils in vitro. The importance of the anticoagulant used during blood collection. Clin Biochem 41:570-575, 2008.
PubMed
20) Ushida Y et al.:Possible chemopreventive effects of bovine lactoferrinon esophagus and lung carcinogenesis in the rat Jpn J Cancer Res 90, 262-267(1999) .
 
21) Kelly RJ, Giaccone G:The role of talactoferrin alpha in the treatment of non-small cell lung cancer. Expert Opin Biol Ther 10:1379-1386, 2010.
PubMed
22) LiuY, Han F, Xie Y, Wang Y:Comparative antimicrobial activity and mechanism of action of bovine lactoferricin-derived synthetic peptides. Biometals 2011.
 
23) Yamauchi K, Tomita M, Giehl TJ, Ellison RT:3rd Antibacterial activity of lactoferrin and a pepsinderived lactoferrin pcptide fragment. Infect Immun 61:719-728, 1993.
 
24) Kumagai Y, Akira S:Identification and functions of patterrrecognition receptors. J Allergy Clin Immunol 125:985-992, 2010.
PubMed
25) Takeda K Akira S:Toll-like receptors in innateimmunity. Int Immunol 17:1-14, 2005.
 
26) Akira S, Takeda K, Kaisho T:Toll-like receptors:critical proteins linking innate and acquired immunity. Nat Immunol 2:675-680, 2001.
PubMed
27) Artis D:Epithelia-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. Nat Rev Immunol 8:411-420, 2008.
 
P.82 掲載の参考文献
1) Arnold RR, Brewer M, Gauthier JJ:Bactericidal activity of human lactoferrin:sensitivity of a variety of microorganisms. Infect Immun 28:893-898, 1980.
PubMed
2) Weinberg ED:Iron and infection. Microbiol Rev 42:45-66, 1978.
PubMed
3) Ellison III RT, Giehl TJ, LaForce FM:Damage of outer membrane of the emeric Gram-negative bacteria by lactoferrin and transferrin. Infect Immun 56:2774-2781, 1988.
 
4) Sorimachi K, Akimoto K, Hattori Y, Ieiri T, Niwa A:Activation of macrophages by lactoferrin:secretion of TNF-atpha, IL-8 and NO. Biochem Mol Biol Int 43:79-87, 1997.
 
5) Hayden MS. Ghosh S:Shared principles in NF-kappaB signaling, Cell 132:344-362, 2008.
PubMed
6) Kawai T, Akira S:Signaling to NF-kappaB by Toll-like receptors. TRENDS Mol Med 13:460-469, 2007.
PubMed
7) Vorland LH:Lactoferrin:a multifunctional glycoprotein. APMIS 107:971-981, 1999.
PubMed
8) Elass-Rochard E, Legrand D, Salmon V, Roseanu A, Trif M et al.:Lactoferrin inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide-binding protein. Infect Immun 66:486-491, 1998.
PubMed
9) Ando K, Hasegawa K, Shindo K, Furusawa K, Fujino K et al.:Human lactoferrin activates NF-kappaB through the Toll-like reccptor 4 patway while it interferes with the lipopolysaccharide-stinlulated TLR4 signaling. FEBS J 277:2051-2066, 2010.
 
P.87 掲載の参考文献
1) Arnold RR, Brewer M, Gauthier JJ:Bactericidal activity of human lactoferrin:sensitivity of a variety of microorganisms. Infect Immun 28:893-898, 1980.
PubMed
2) Aguilera O, Andres MT, Heath J, Fierro JF, Douglas CWI:Evaluation of the antimicrobial effect of lactoferrin on Porphyromonas gingivalis. Prevotela intermedia and Prevotella nigrescens. FEMS Immunol Med Microbiol 21:29-36, 1998.
 
3) Wakabayashi H, Abe S, Teraguchi S. Hayasawa H, Yamaguchi H:Inhibition of hyphal growth of azoleresistant strains of Candida albicans by triazole antifungal agents in the presence of lactoferrin-related compounds. Antimicrob Agents Chemother 42:1587-1591, 1998.
PubMed
4) Wakabayashi H, Yamauchi K, Kobayashi T, Yaeshima T, Iwatsuki K et al.:Inhibitory effects of lactoferrin on growth and biofilm formation of, Porphyromonas gingivalis and Prevotella intermedia. Antimicrob Agents Chemother 53:3308-3316, 2009.
PubMed
5) Wakabayashi H, Kondo I, Kobayashi T, Yamauchi K, Toida T et al:Periodontitis, periodontopathic bacteria and lactoferrin. Biometals 23:419-424, 2010.
PubMed
6) 近藤一郎, 小林哲夫, 若林裕之, 山内恒治, 岩附慧二・他:歯周炎患者におけるウシラクトフェリン経口投与の影響. 日歯保存誌 51:281-291, 2008.
Medical*Online
7) Shin K, Horigome A, Wakabayashi H, Yamauchi K, Yaeshima T et al.:In vitro and in vivo effects of a composition containing lactoperoxidase on oral bacteria and breath odor. J Breath Res 2:017014(5pp) , 2008.
 
8) Shin K, Yaegaki K, Murata T, Ii H, Tanaka T et al.:Effects of a composition containing lactoferrin and lactoperoxidase on oral malodor and salivary bacteria:a randomized, double-blind, crossover, placebo-controlled clinical trial. Clin Oral Invest 15:485-493, 2011.
 
9) Shimizu E, Kobayashi T, Wakabayashi H, Yamauchi K, Iwatsuki K et al.:Effects of orally administered lactoferrin and lactoperoxidase-containing tablets on clinical and bacteriological profnes in chronic periodontitis patients. Int J Dent 2011:405139(pages) , 2011.
 
10) 清水英寿, 若林裕之, 小林哲夫, 吉江弘正:歯周病患者におけるラクトフェリン + ラクトパーオキシダーゼ錠菓摂取による体感効果. 日歯東洋医誌 30:1-7, 2011.
 
P.92 掲載の参考文献
1) Qamruddin AO, Alkawash MA, Soothill JS:. Antibiotic susceptibility of Stenotrophomonas maltophilia in the presence oflactoferrin. Antimicrob Agents Chemother 49:4425-4426. 2005,
PubMed
2) WaKabongo M, Stucki ZN, Torbert DP, Olweny J:Effect of bovine lactoferrinon the MICs of ampicillin sulbactam(UNASYN) , amoxicillin clavulanic acid(Augmentin) , ticarcillin clavulanate (Timentin) . and piperaciilin-tazobactam(ZOSYN) , against clinical and environmental isolates of motile Aeromonas. J Am Osteopath Assoc 105:25-26, 2005.
PubMed
3) Alkawash M, Head M, Alshami I, Soothill JS:The effect of human lactoferrin on the MICs of doxycycline and rifampicin for Burkholderia cepacia and Pseudomonas aeruginosa strains. J Antimicrob Chemother 44:385-387, 1999.
PubMed
4) Fowler CE, Soothill JS, Oakes L:MICs of rifampicin and chloramphenicol for mucoid Pseudomonas aeruginosa strains are lower when hLimaii lactoferrin is present. J Antimicrob Chemother 40:877-879. 1997.
 
P.98 掲載の参考文献
1) Serra X, Ruiz-Ramirez J, Arnau J, Gou P:Texture parameters of dry-cured ham m. bicepsfemoris samples dried at different levels as a function of water activitv and water eontent. Meat Sci 69:249-254, 2005.
 
2) Andres AI, Ventanas S, Ventanas J, Cava R, Ruiz J:Physicochemical changes throughout the ripening of dry cured hams with different salt content and processing conditions. Eur Food Res Technol 221:30-35. 2005.
 
3) Lonnerdal B, Iyer S:Lactoferrin:Molecular structure and biological function. Annu Rev Nutr 15:93-110, 1995.
PubMed
4) Kim WS, Shimazaki K:Offence and defense mechanisin between lactoferrin and microoranisms. ラクトフェリン2007. 日本医学館, 2007, p9-17.
 
5) Tomita M, Wakabayashi H, Shin K, Yamauchi K, Yaeshima T et al.:Twenty-five years of research on bovine lactoferrin applications. Biochimie 91:52-57, 2009.
PubMed
6) Naidu AS:Activated lactoferrin -A new approach to meat safety. Food Technol 56:40-45, 2002.
 
7) Witte VC, Krause GF, Bailey ME:A new extraction method for determining-thiobarbituric acid values of pork and beef during storage. J Food Sci 35. 582-585, 1970.
 
8) 高坂和久:肉製品の鮮度保持と測定. 食品工業 18:105-111. 1975.
 
9) Blois MS:Antioxidant determination b the use of stable free radical. Nature 181:1199-1200, 1958.
 
10) Bellamy W, Wakabayashi H, Takase M, Kawase K, Shimamura S et al:Killing of Candida albicans by lactoferricin B, a potent antimicrobial peptide derived from thc N-terminal region of bovine lactoferrin, Med Microbial Immunol 182:97-105, 1993.
 
11) Ryu YK, Rahman MM. Kafley S, Shimazaki K, Kim WS:Antioxidant activity of lactoferrin, transferrin, α-lactalbumin and β-lactoglobulin. ラクトフェリン 2009. 日本医学館, 2009, p132-136.
 
P.103 掲載の参考文献
1) 平成22年国民生活基礎調査の概況(厚生労働省)
 
2) Ono T. Murakoshi M, Suzuki N. Iida N, Ohdera M et al.:Potent anti-obesity effect of enteric-coated lactoferrin:decrease in visceral fat accumulation in Japanese men and women with abdominal obesity after 8-week administration of enteric-coated lactoferrin tablets. Br J Nutr 104(11) :1688-169. 5, 2010.
PubMed
3) Kishida T, Uno K, Kishi A, Onishi T, Matsubara Y:Enhancement of immunological finctions by lactobacillus brevis subsp. coagulans. The Clincal Report 27(9) :3701-3707, 1993.
 
4) Kishi A, Uno K, Matsubara Y, Okuda C, Kishida T:Effect of the oral administration of lactobacillus brevis subsp. coagulans on interferon-a producing capacity in humans. J of American College of Nutrition 5(4) :408-412, 1996.
 
5) 長谷川秀夫:ラブレ死菌による腸年齢改善及び感染防御効果. New Food Industry 49(8) :9-13, 2007.
 
6) Ono T, Morishita S, Fujisaki C, Ohdera M, Murakoshi M et al.:Effect of pepsin arid trypsin on the antiadipogenic action of lactoferrin against pre-adipocytes derived from mesenteric fat. Br J Nutr 105(2) :200-211, 2011.
 
7) Nagashima K, Hisada T, Satou M, Mochizuki J:Application of new primer-enzyme combinations to terminal restriction fragment length polymorphism profiling of bacterial populations in human feces. Appl Environ Microbiol 69(2) :1251-1262, 2003.
 
8) Nageshima K, Mochizuki J, Hisada T, Suzuki S, Shimomura K:Phylogenetic analysis of 16S ribosomal RNA gene sequences from human fecal microbiota and improved utility of terminal restriction fragment length polymorphism profiling. Bioscience and Microflora 25(3) 199-107, 2006.
 
9) Kim W, Ohashi M, Tanaka T, Kumura H, Kim G, et al.:Growth-promoting effects of lactoferrin on L. acidophilus and Bifidobacterium spp. Biometals 17:279-283, 2004.
 
10) Kim W, Rahman M, Kumura H, Shimazaki K:Comparison of growth promoting effects on bifidobacterium spp. by bovine lactoferrin hydrolysates. Biocience Microflora 24(4) :119-123, 2005.
 
11) Kawaguchi S, Hayashi T, Masago N, Okuyama K, Suzuki T et al.:Studies on the effect of lactoferrin added milk on low body birth weight infants. Mainly on change in intestinal bacterial flora. Perinatal Medicine 19(4) :557-562, 1989.
 
12) Inoue R, Tsukahara T, Noda M, Bukawa W, Matsubaranbara N et al.:Oral administration of a heat-killed cell preparation of Enterococcus facialis strain EC-12 stimulates the gene expression of Na+-K +-2Cl-Co-transpoeter 1 in rat ileal epithelial cells. Biosci Biotechnol Biochem 71(3) :807-810, 2007.
 
P.111 掲載の参考文献
1) 高柳直己, 新飯田裕一, 千葉峻三:ラクトフェリン炎症. 免疫のChemical mediatorとしての再計価. 小児科臨床 39:1287-1293, 1986.
 
2) Baker EN, Baker HM:Astructural framework for understanding the multifunctional character of lactoferrin. Biochimie 91:3-10. 2009.
 
3) 児玉明彦:和歌山, 大阪地方におけるビフィズス菌分離成績と人乳カゼイン, ラクトフェリンのビフィズス菌増殖能について. 日児誌 187:1000-1013. 1983.
 
4) Yoshioka H, Iseki K, Fujita K.:Development and differences of intestinal flora in the neonatal period in breast-fed and bottle-fed infants. Pediatrics 72:317-321, 19. 83.
 
5) 川口 茂, 林 智靖, 真砂野仁, 奥山和男, 鈴木 隆・他:低出生体重児に対するラクトフェリン添加乳の効果に関する検討-主に腸内細菌叢の変化について. 周産期医学 19:557-562. 1989.
 
6) 冨田信一, 魚谷孝之, 松山 惇:ラクトフェリンのBifidobacterium菌体への結合性と増殖性との関係. ラクトフェリン2007. 日本医学館. 2007. p141-147.
 
7) Miller-Catchpole R, Kot E, Haloftis G, Furmanov Sarid Bezkorovainy A:Lactoferrin can supply iron for the growth of Btfidobacterium breve. Nutr Res 17:205-213, 1997.
 
8) Gray-Owen SD, Schryvers AB:Bacterial transferrin and lactoferrin receptors. Trends Microbiol 4:185-191, 1996.
PubMed
9) Rahman MM, Kim WS, Ito T, Kumura H, Shimazaki K:Visualization of bovine lactoferrin binding to Bifidobacteria. Biosci Microflora 26:75-79, 2007.
 
10) Kim WS, Tanaka T, Kumura H, Shimazaki K:Lactoferrin-binding proteins in Bifidobacterium bifidum. Biochem Cell Biol 80:91-94, 2002.
PubMed
11) Rahman MM. Kim WS, Kumura H, Shimazaki K:Bovine lactoferrin region responsible for binding to bifidobacterial cell surface proteins. Biotechnol Lett 31:863-868, 2009.
 
12) 大戸絵里子, 島崎敬一:ラクトフェリンおよびそのフラグメント間の相互作用. ラクトフェリン2007. 日本医学館. 2007. p148-153.
 
13) Raje CI, Kumar S, Harle A, Nanda JS, Raje M:The macrophage cell surface GAPDH is a novel transferrin receptor. J Biol Chem 282:3252-3261, 2007.
PubMed
14) Carrete R, Reguant C, Bordons A, Constanti M:Relationship between a stress membrane protein of Oenococcus oeni and GAPDH. Appl Biochem Biotechnol 127:43-51, 2005.
PubMed
15) 石谷良一:神経細胞アポトーシスでのGAPDHの役割. 生化学 69:1107-1111, 1997.
 
16) Sirover MA:New insights into anorld protein:the functional diversity of mammalian GAPDH. Biochim Biophys Acta 1432:159-184, 1999.
PubMed
17) Sirover MA:On the functional diversitv of GAPDH. Biochemical mechanisms and regulatory control. Biochim Biophys Acta 1810:741-751. 2011.
PubMed
18) Tanaka T, Abe Y, Inoue N, Kim WS, Shimazaki K et al.:The detection of bovine lactoferrin binding Protein on Trypanosoma brucei. J Vet Med Sci 66:619-625, 2004.
PubMed
19) Hara MR, Cascio MB, Sawa A:GAPDH as a sensor of NO stress. Biochim Biophys Acta 1762:502-509, 2006.
PubMed
20) Morigasaki S, Shimada K, Ikner A, Yanagida M, Shiozaki K:Glycolytic cnzyme GAPDH promotes peroxide stress signaling through multistep phosphorelay to a MAPK cascade. Mol Cell 30:108-113, 2008.
PubMed
21) Lottenberg R, Broder CC, Boyle MD, Kain SJ, Schroeder BL et al.:Cloning, sequence analysis, and expression in Escherichia coli of a streptococcal plasmin receptor. J Bacteriol 174:5204-5210, 1992.
PubMed
22) Gase K, Gase A, Schirmer H and Malke H:Cloning, sequencing and functional overexpression of the Streptococcus equisimilis H46A gapC gene encoding a GAPDH that also functions as a plasmin(ogen)-binding protein. Purification and biochemical characterization of the protein. Eur J Biochem 239:42-51, 1996.
 
23) Bergmann S, Rohde M, Hammerschmidt S:GAPDH of Streptococcus pneumoniae is a surface-displayed plasininogen-binding protein. Infect Immun, 72:2416-2419, 2004.
PubMed
24) Gozalbo D, Gil-Navarro I, Azorin I, Renau-Piqueras J, Martinez JP et al.:The cell wall-associated GAPDH of Candida albicans is also a fibronectin and laminin binding protein. Infect Immun 66:2052-2059, 1998.
PubMed
25) Alvarez RA, Blaylock MW, and Baseman JB:Surface localized GAPDH of Mycoplasma genitalium binds mucin. Mol Microbiol 48:1417-1425. 2003.
PubMed
26) Kinoshita H, Uchida H, Kawai Y, Kawasaki T, Wakahara N et al.:Cell surface Lactobacillus plantarum LA 318 GAPDH adheres to hurnan colonic mucin J Appl Microbiol 104:1667-1674, 2008.
 
27) Modun B, Williams P:The staphylococcal transferrinbinding protein is a cell wall GAPDH. Infect Immun 67:1086-1092, 1999.
PubMed
28) Kinoshita H, Wakahara N Watallabe M, Kawasaki T, Matsuo H et al.:Cell surface GAPDH of Lactobacillus plantarum LA 318 recognizes human A and B blood group antigens. Res. Microbiol 159:685-691, 2008.
 
P.119 掲載の参考文献
1) 島崎敬一:ラクトフェリンの多機能性をどう説明するか. ミルクサイエンス 53(4) :365-368, 2004.
 
2) Shimazaki K, Kushida T:Apreliminary approach to creating an overview of lactoferrin multi-functionality utilizing a text mining method. Biometals 23(3) :453-463, 2010.
 
3) 櫛田達矢, 島崎敬一:テキストデータ分析ツールを用いたラクトフェリンの多機能性に関する情報整理と知識抽出. ラクトフェリン2009. (第3回ラクトフェリンフォーラム実行委員会) . 日本医学館, 東京, 2009, p184-190.
 
4) Weeber M, Vos R, Klein H, De Jong-Van Den Berg LT, Aronson AR et al.:Generating hypotheses by discovering implicit associations in the literature:a case report of a search for new potential therapeuticuses for thalidomide. J Am Med Inform Assoc 10(3) :252-259, 2003.
PubMed
5) Swanson DR:Fish oil, Raynaud's syndrome, and undiscovered public knowledge. Perspect Biol Med 30(1) :7-18. 1986.
PubMed
6) Kushida T, Asanuma T, Okuda Y, Shidahara Y, Takagi T:Collection of Disease Networks by Hybrid Curation Method and the Application for Pathway Analysis. International Conference on Complex, Intelligent and Software Intensive Systems:800-806, 2009.
 
7) Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT et al.:Cytoscape:a software environment for integrated models of biomolecular interaction networks. Genome Research 13(11) :2498-2504, 2003.
PubMed
8) Machnicki M, Zimecki M, Zagulski T:Lactoferrin regulates the release of tumour necrosis factor alpha and interleukin 6 in vivo. Int J Exp Pathol 74(5) :433-439, 1993.
PubMed
9) Ognjanovic S, Bao S, Yamamoto SY, Garibay-Tupas J, Samal B et al.:Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J Mol Endocrinol 26(2) :107-117, 2001.
PubMed
10) Crouch SP, Slater KJ, Fletcher J:Regulation of cytokine release from mononuclear cells by the iron-binding protein lactoferrin. Blood 80(1) :235-240, 1992
PubMed
11) Adamik B, Zimecki M, Wlaszczyk A, Berezowicz P, Kubler A:Lactoferrin effects on the in vitro immune response in critically in patients. Arch Immunol Ther Exp(Warsz) 46(3) :169-176, 1998.
PubMed
12) Srivastava CH, Rado TA, Bauerle D, Broxmeyer HE:Regulation of human bone marrow lactoferrin and myeloperoxidase gene expression by tumor necrosis factor-alpha. J Immunol 146(3) :1014-1019, 1991.
PubMed
13) Lo JC, Wang Y, Tumanov AV, Bamji M, Yao z et al.:Lymphotoxin beta receptor-dependcnt control of lipid homeostasis. Sciellce 316(5822) :285-288, 2007.
 
P.125 掲載の参考文献
1) Jin Yz, Nannai S, Dacheux F, Dacheux Jl, Okamura N:Direct evidence for the secretion of lactoferrin and its binding to sperm in the porcine epididymis. Molecular Reproduction and Development 47:490-496, 1997.
 
2) Das SK, Jian J, Johnson DC. Dey SK:Differential spatiotemporal regulation of lactoferrin and progcsterone receptor genes on the mouse uterus by primary estrogen, catechol estrogen, and xenoestrogen. Endocrinology 139:2905-2915, 1998.
 
3) Wared PP, Mendoza-Meneses M, Mulac-Jericevic B, Cunningham GA, Saucedo-Cardenas O et al:Restricted patioemporal expression of lactoferrin during murine embryonic development. Endocrinology 140:1852-1860, 1999.
 
4) Kida K, Baba E, Torii R, Kawate N, Hatoya S et al.:Lactoferrin expression in the canine uterus during the estrous cycle and with pyometra. Theriogenoogy 66:1325-1333. 2006.
PubMed
5) 金子一幸:分娩後の子宮内細菌が繁殖性に影響を及ぼすメカニズムおよびその対策. MPアグロジャーナル 6:9-11. 2011.
 
6) Williams EJ, Fischer DP, Noakes DE, England GC et al.:The relationship between uterine pathogen growth density and ovarian function in the postpartum dairy cow. Theriogenology 68(4) :549-559, 2007.
PubMed
7) Williains EJ, Herath S, England GCW, Dobson H, Bryant CE et al.:Effect of Escherichia coli infection of the bovine uterus from the whole animal to the cell. Animal 2:1153-1157. 2008.
 
8) Herath S, Lilly ST, Fischer DP, Williams EJ, Dobson H et al:Bacterial lipopolysaccharide induces an endocrine switch from prostaglandin F2 alpha to prostaglandin E2 in bovine endometrium. Endocrinology 150(4) :1912-1920, 2009.
PubMed
9) Dixon SN and Gibbons RA:Proteins in the uterine secretions of the cow. J Reprod Fertil 56:119-127, 1979.
PubMed
10) Takahashi H, Iga K, Sato T, Takahashi M, Okano A:Isolation and culture of bovine endometrial epithelial cells in a seurm-free culture system. J Reprod Dev 47:181-187, 2001.
 
11) Prakash BS, Meyer HH, Schallenberger E, van de Wiel DF:Development of a sensitive enzymeimmunoassay (EIA) for progesterone determination in unextracted bovine plasma using the second antibody technique. J Steroid Biochem 28:623-627, 1987.
PubMed
P.131 掲載の参考文献
1) 農林水産省農林水産技術会議, 魚と貝のバイオテクノロジー -安全で信頼できる魚と貝を目指して-. 農林水産研究開発レポート. 16:8-15, 2006.
 
2) 水産用ワクチンの適正使用について (www.tomita-pharma.co.jp/members/pdf_as/topics_h180727.pdf)
 
3) 嶋村一郎:水産用ワクチンについて. 徳島水研だより 38:3-4. 1999.
 
4) 岡本康孝:北太平洋と日本におけるさけます類の資源と増殖. SALMON情報. 2:26-27, 2008.
 
5) 社団法人日本水産資源保護協会, IV章 我が国におけるヒメマスの増養殖. 湖沼環境の基盤情報整備事業報告書:123-155, 1974. (www.fish-jfrca.jp/04/pdf/lake/shikotsu/006_sikotu.pdf)
 
6) Yoshida T, Sakai M, Kitao T, Khlil S. M, Araki S, et al. Immuno-modulatory effects of the fermented products of chicken egg. EF203 on rainbow trout. Oncorhynchus myleiss Aquaculture 109:207-214, 1993.
 
7) Park B, H, Fikrig S, M, Smithwick. Infection and nitroblue-tetrazolium reductic ns by neutro-phils:a diagnostic aid. E, M, :Lancet II 532-534, 1968.
 
8) Kakuta I:Reduction of stress response in carp. Cyprinuscarpio L., held under deteriorating environmental conditions, by oral administration of bovine lactoferrin. Fish Dis:21:161-167, 1998.
 
9) 角田 出, ラクトフェリンによるストレス軽減および生体防御活性増強 -魚類への投与効果-. バイオインダストリー 15:23-33, 1998.
 
10) Beckmann RP, Mlzzen L A, Interaction of Hsp70 with newly synthesized proteins:Implications for protein folding and assembly. Science. 248 850-854, 1990.
 
11) 高瀬清美, 角田 出:ラクトフェリンによる化学療法剤処理魚の副作用軽減. 薬学雑誌 129:1449-1460. 2007.
 
12) 角田 出:ラクトフェリンの投与がキンギョの成長および血液性状に及ぼす影響. 水産増殖 44:419-426, 1996.
 
P.137 掲載の参考文献
1) Suzuki YA. and Lonnerdal B:Lactoferrin:structure, functions, and applications. Funct Food Rev 2:69-79, 2010.
 
2) 小島隆矢:Excelで学ぶ共分散構造分析とグラフィカルモデリング. オーム社, 2007. p92-122, p186-222.
 
3) 堺 章:新訂目でみるからだのメカニズム. 医学書院, 2007, p166.
 
4) エレイン N マリーブ:人体の構造と機能. 医学書院, 2007, p99-100.
 
5) Takeuchi T, Jyonotsuka T, Kamemori N, Kawano G, Shimizu H et al:Enteric-formulated lactoferrin was more effectively transported into blood circulation from gastrointestinal tract in adult rats. Exp Physiol 91:1033-40, 2006.
PubMed
6) Saito S. Takayama Y, Mizumachi K and Suzuki C:Lactoferrin promotes hyaluronan synthesis in human dermal fibroblasts. Biotechnol Lett 33:33-39, 2011.
PubMed
7) 輪千浩史:糖尿病誘発マウスにおけるラクトフェリンの創傷治癒促進効果. ラクトフェリン. 日本医学館, :2009, p46-54.
 
P.141 掲載の参考文献
1) 辻晋作, 館正弘, 平林慎一:比較的簡便な実験的褥瘡モデルによる褥瘡発生原因の検討(第1報) . 日本褥瘡学会誌 4:83-87, 2002.
Medical*Online
2) Stadler I, Zhang RY, Oskoui P, Whittaker MS, Lanzafame RJ:Development of a simple, noninvasive. clinically relevant model of pressure ulcers in themouse. J Invest Surg 17:221-227. 2004.
 
3) Sugama J, Sanada H, Nakatani T et al.:Pressureinduced ischemic wound healing with beterial inoculation in the rat. Wounds 17:157-168, 2005.
 
4) Mizuno K, Wachi H. Sato F, Onoue S, Sakamoto Y et al:Characteristic expression of connective tissue components and matrix metalloproteinases(MMPs) during thc development of pressure ulceralions. Inflamm Regen 28:47-52. 2008.
 
5) 輪千浩史:糖尿病誘発マウスにおけるラクトフェリンの創傷治癒促進効果. ラクトフェリン2009. (第3回ラクトフェリンフォーラム実行委員会・編) , 2009, p46-54.
 
6) 森口隆彦:創傷治癒の基礎. 褥瘡会誌 2:225-235, 2000.
Medical*Online
7) Bergers G, Brekken R, McMahon G, Vu TH, Itoh T et al.:Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:737-744, 2000.
PubMed
8) Sabine AE, Manuel K, Andreas K, Bent B. Sandra K, Leena B-T et al:Differential proteomic analysis distinguishes tissue repair biomarker signatures in wound exudates obtained from normal healing and chronic wounds. J Proteome Res 9:4758-4766, 2010.
 
9) Liu Y, Min D, Bolton T, Nube V, Twigg SM et al.:Increased matrix metalloproteinase-9 predicts poor wound healing in diabetic foot ulcers. Diabetes Care 32:117-119, 2009.
 
10) Ladwig GP, Robson MC, Liu R, Kuhn MA, Muir DF et al.:Ratios of activated matrix metalloproteinase-9 to tissue inhibitor of matrix metalloproteinase-1 in wound fluids are inversely correlated with healing of pressure ulcers. Wound Repair Regen 10:26-37, 2002.
PubMed
11) Suzuki YA, Shin K, Lennerdal B:Molecular cloning and functional expression of human intestinal lactoferrin receptor. Biochemistry 40:15771-15779, 2001.
 
12) Conneely OM:Anti-inflammatory activities of lactoferrin. J Am Coll Nutr 20:389S-397S. 2001.
PubMed
13) Takayama Y, Mizumachi K:Effects of lactoferrin on collagen gel contractile activity and myosin light chain phosphorylation in human fibroblasts. FEBS Lett 508:111-116, 2001.
PubMed
14) Takayama Y, Mizumachi K, Takezawa T:The bovine lactoferrin region responsible for promoting the collagen gel contractile activity of human fibroblasts. Biochem Biophys Res Commun 299:813-817, 2002.
PubMed
15) Hayashida K, Kaneko T, Takeuchi T, Shimizu H, Ando K et al:Oral administration of lactoferrin inhibits inflammation and nociception in rat adjuvant-induced arthritis. J Vet Med Sci 66:149-154, 2004.
PubMed
P.147 掲載の参考文献
1) Martinez G, Costantino G, Clementi A, Puglia M, Clementi S et al.:Cisplatin-induced kidney injury in the rat:L-carnitine modulates the relationship between MMP-9 and TIMP-3. Exp Toxicol Pathol 61:183-188, 2009.
 
2) Chang B, Nishikawa M, Sato E, Utsumi K, Inoue M:L-Carnitine inhibits cisplatin-induced injury of the kidney and small intestine. Arch Biochem Biophys 405:55-64, 2002.
PubMed
3) Atessahin A, Yilmaz S, Karahan I, Ceribasi AO, Karaoglu A:Effects of lycopene against cisplatininduced nephrotoxicity and oxidative stress in rats. Toxicol 212:116-123, 2005.
 
4) Naghizadeh B, Boroushaki MT, Mashhasian NV. Mansouri SMT:Protective effects of crocin against cisplatin-induced acute renal failure and oxidative stress in rats. Iran Biomed J 12:93-100, 2008.
 
5) Venkatachalam MA, Bernard DB, Donohoe JF. Levinsky NG:Ischemic damage and repair in the rat proximal tubule:Differences am(mg the S1, S2. and S3 segments. Kidney Int l4:31-49. 1978.
 
6) Dobyan DC, Levi J, Jacobs C, Kosek J, Weiner MW:Mechanism of cis-platinum nephrotoxicity:H. Morphologic observations. J pharmacol Exp Ther 213:551-556, 1980.
 
7) Stein JH, Fried TA:Experimcntal models of nephrotoxic acute renal failure. Transplant Proc 17:Suppl 1. 72-80, 1985.
 
8) Nishikawa M, Nagatomi H, Chang BJ, Sato E, Inoue M:Targeting superoxide dismutase to renal proximal tubule cells inhibits mitochondrial injury and renal dysfunction induced by cisplatin. Arch Biochem Biophys 387:78-84, 2001.
 
9) Koike D, Makino I:Protective effect of lactoferrin on caerulein-induced acute pancreatitis in rats. Digest 54:84-90, 1993.
PubMed
10) Hayashida K, Takeuchi T. Shimizu H, Ando K, Harada E:Lactoferrin enhances opioid-mediated analgesia via nitric oxide in the rat spinal cord. Am J Physiol Regul Integr Comp Physiol 285:306-312, 2003.
 
11) Tsubota A, Yoshikawa T, Narai K, Mitsunaga M, Yumoto Y et al.:Bovine loctoferrin potently inhibits liver mitochondrial 8-OHdG levels and retrieves hepatic OGGI activities in Long-Evans Chinliamon rats. J Hepatol 48:486-493, 2008.
 
12) Cornish J, Callon KE, Naot D, Palmano KP, Banovic T et al.:Lactoferrin is a potent regulator of bone cell activity and increases bone formation in vivo. Endocrinol 145:4366-4374, 2003.
 
13) Abrink M, Larsson E, Gobl A, Hellman L:Expression of lactoferrin in the kidney:Implications for innate immunity and iron metabolism. Kidney Int 57:2004-2010, 2000.
PubMed
14) Zimecki M, Artym J, Chodaczek G, Kocieba M, Kuryszko J et al.:Immunoregulatory function of lactoferrin in immunosuppressed and autoimmune animals. Post Hig Med Dosw 61:283-287, 2007.
 
15) Safirstein R, Miller P, Guttenplan JB:Uptake and metabolism of cisplatin by rat kidney. Kidney Int 25:753-758, 1984.
PubMed
P.152 掲載の参考文献
1) Nitta K:Yuukigouseikagaku 49:968. 979, 1991.
 
2) Fausel CA:Oncology 23. 88-90, 2009.
PubMed
3) Shewach DS. Kuchta RD, Chem, Rev:109:2859-2861, 2009.
PubMed
4) Takase K, Kakuta I:Yakushi 129:1449-1460, 2007.
 
5) Takase K, Kakuta I:Yakushi 131:1473-1481. 2011.
 
6) Smith CA, Anderg. on BF, Baker HM, Baker EN:Acta Crystallogr D Biol Crystallogr 50:302-316, 1994.
 
7) Yoshise RE, Matsumoto M, Chiji H, Kuwata H, Shin K, Yamauchi K, Tamura Y, Tanaka T. Kumura HL Shimazaki K, Milchwissenschaft 62:446-450, 2007.
 
8) Shimizu H:Food Res 604:54-59, 2005.
 
9) Smith LS:Fish Nutrition 2nd. (ed HalverJ. E) . academic Press, New York, 1989, p 331-421.
 
10) Bowen SH:Nature(London) :260:137-138, 1976.
 
11) Maier KJ, Tullis RE, J. Fish Biol:25:151-185, 1984.
 
12) SocietyofJapanese Pharmacopoeia:Nihon Yakkyokuho Kaisetsusho. 2nd ed. Hirokawa Publishing Co, Tokyo. 1986. p349.
 
13) Masson PL, Heremans JF, Dive CH, Clin. Chem. Acta:14:735-739, 1966.
 
14) Arnold RR, Brewer M, Gauthier JJ:Infect. Immun 28:983-898, 1980.
 
15) Van der Strate BW, L Beljaars, Molema G, Harmsen MC, Merjer DK. Antiviral Res 52:225-239., 2001.
 
16) Wakabayashi H Yamauchi K, Taraguchi S, Hayasawa H, Uchida K, Yamaguchi, H:J Antimicrob Chemother 46, 595-601, 2000.
 
17) Tanaka T, Omata Y, Saito A, Igarashi I, Suzuki N, Shimazaki K, :J. Vet. Med. Sic 58:61-65, 1996.
 
18) Kakuta I, Kurokura H:Fish. Pathol 30:289-290, 1995.
 
19) Lu L, Hangoe G, Oliff A, Chen LT, Shen R-N, Broxmeyer HE:Cancer Res 47:4184-4188. 1987.
 
20) Bezault J, Bhimani R, wiprovnick J, Furmanski P, :Cancer Res 54:2310-2312. 1994.
PubMed
21) Yoo YC, Watanabe S, Watanabe R, Hata K, Shimazaki K, Azuma I:Jpn. J. Cancer Res 40. 257-262, 1997.
 
22) Sekine K, Watanabe E, Nakamura J, Takasuka N. Kim DJ, Asamoto M, Krutovskikh v, Baba-Toriyama H, Ota T, Moorc MA, Masuda M, Sugimoto H, Nishino H, Kakizoe T, Tsuda H:Jpn. Cancer Res 88:523-526. 1997.
 
23) Yamada M, Hongoh M, Ujie H, Okuno H, Nishimura M, Ueno M, Toyoda T, Hayashi Y, Okuyama S:Nippon Heikatsukin Gakkai Zasshi 25:308-310. 1989.
 
P.156 掲載の参考文献
1) Otsuki K, Yoda A, Hirose K, Shimizu Y, Saito H et al.:Salivary Lactoferrin in Neonates with Chorioamnionitis. Showa Univ J Med Sci 9(1) :39-44, 1997.
 
2) Otsuki K, Yoda A, Toma Y. Shimizu Y, Saito H et al.:Lactoferrin and Interleukin-6 Interaction in amniotic infection. Adv Exp Med Biol 443:267-71, 1998.
PubMed
3) Sawada M, Otsuki K, Yakuwa K, Mitsukawa K, Nagatsuka M et al, :Cervical inflammatory cytokines and other markers in cervical mucus of pregnant women with lower genital tract infections. Int J Gynecol Obstet. 117-121, 2006.
 
4) 大槻克文, 斎藤裕, 矢内原巧:サンドイッチELISA法を用いた新生児唾液中ラクトフェリン濃度の測定. 日本産科婦人科栄養・代謝研究会誌 2(1) :67, 1996.
 
5) 依田暁, 大槻克文, 藤間芳郎, 清水幸子, 斎藤裕, 他:絨毛膜羊膜炎における羊水中Lactoferrin測定の臨床的意義. 日本産科婦人科栄養・代謝研究会誌 3 (1) :57-58, 1997.
 
6) Otsuki K, Yoda A, Mitsuhashi Y, Toma Y, Shimizu Y, et al.:Amniotic fluid lactoferrin in intrauterine infection. Placenta Mar-Apr 20(2-3) :175-9, 1999.
 
7) Otsuki K, Yoda Y, Mitsuhashi Y, Shimizu Y. Saito H et al.:Isolation and detection of human lactoferrin binding protein in human amniotic membrane. Lactoferrin:Structure, Function and Applications 343-346, 2000.
 
8) 齋藤裕, 大槻克文. 依田暁, 矢内原巧:子宮内感染と早産-子宮内感染におけるラクトフェリンの感染防御機構について. 周産期学シンポジウム 16:111-114, 1998.
 
9) 依田暁, 大槻克文, 三橋裕一, 清水幸子, 齋藤 裕, 他:絨毛膜羊膜炎をきたした早産症例における羊水中 ラクトフェリンとIL-6の動態. 日本新生児学会雑誌 34(3) :506-510, 1998.
 
10) Saito H, Otsuki K. Mitsuhashi Y, Yoda Y, Yanaihara A et al.:Role of lactoferrin in the prevention of preterm delivery. Lactoferrin:Structure, Function and Applications 347-352, 2000.
 
11) Mitsuhashi Y, Otsuki K. Yoda Y, Shimizu Y, Saito H et al.:Effect of lactoferrin on lipopolysaccharide (LPS) induced preterm delivery in mice. Acta Obstet Gynecol Scand 79:355-358, 2000.
 
12) Sherman MP, Otsuki K, Lennerdal BL:Preventing Escherichia coli growth on cervical epithelium. Pediatr Res 49:232A. 2001.
 
13) Otsuki K. Lonnerdal BL, Sherman MP:Lactoferrin:Bacterial opsonin for macrophages?. Biochemistry and Cell Biology 80:158, 2002.
 
14) Otsuki K, Lonnerdal BL, Sherman MP:Bacterial growth on human cervical epithelia:A new assay for testing killing by lactoferrin. Biochemistry and Cell Biology 80:165, 2002.
 
15) Sasaki Y, Otsuki K, Hasegawa A, Sawada M, Chiba H, Negishi M, Nagatsuka M, Okai T:Preventive effect of recombinant human Lactoferrin on lipopolysaccharide-induced preterm delivery in mice. Acta Obstet Gynecol Scand 83:1035-1038, 2004.
PubMed
16) Otsuki K, Sasaki Y, Hasegawa A, Sawada M, Mitsukawa K et al.:Lactoferrin concentrations in cervical mucus of pregnant women with and without infection. Am J Obstet Gynecol 191:S75, 2004.
 
17) Hasegawa A, Otsuki K Sasaki Y, Sawada M, Mitsukawa K, et al.:Preventive effect of recombinant human lactoferrin in a rabbit preterm delivery model Am J ObstetGynecol 192:1038-1043, 2005.
 
18) Otsuki K, Hascgawa A, Sasaki Y, Sawada M, Yakuwa K, et al:Potential of lactoferrin in the prevention of preterm delivery, Taiwanese J Obstet Gynecol 44:123-127, 2005.
 
19) Otsuki K, Yakuwa K, Sawada M, Hasegawa A, Sasaki Y, et al.:Recombinant human lactoferrin has a preventive effects on lipopolysacc. haride-induced preterm delivery and production of inflaminatory cytokines. J Perinat Med 33:320-323, 2005.
 
20) 大槻克文 長谷川明俊 澤田真紀 満川香織 千葉 博・他:ラクトフェリンによる体内での炎症性サイトカイン産生抑制を解した早産予防の試み. Milk Science 53(4) :304-305, 2004.
 
21) 長谷川明俊, 大槻克文, 佐々木 康, 澤田真紀, 満川 香織・他:ラビット早産モデルにおけるlactoferrinの早産防止効果. Milk Science 53(4) :306-308, 2004.
 
22) 長谷川明俊, 大槻克文, 佐々木康, 澤田真紀, 千葉 博・他:マウス早産モデルにおけるRecombinant human lactoferrinの早産防止効果. 日本周産期・新生児医学会雑誌 40(1) :35-39, 2004.
Medical*Online
23) 大槻克文:超早産の病態. 予後及び予防への展望 Lactoferrinによる超早産予防の可能性. 日本周産期・新生児医学会雑誌 40(4) :759-762, 2004.
 
24) Romero R, Yoon BH, Mazor M. et al. The diagnostic and prognostic value of amniotic fluid white blood cell count, glucose, interleukin-6, and gram stain in patients with preterm labor and intact membranes. Am. J. Obstet Gynecol 169:805-16, 1993.
PubMed
25) Yoon BH, Park CW, Chaiworapongsa T. Intrauterine infection and the development of cerebral palsy. Br J Obstet Gynecol 110(Suppl 20) :124-7, 2003.
 
26) Dudley DJ. Pre-term labor:an intra-uterine inflammatory response syndrome? J Reprod Immunol 36:93-109, 1997.
PubMed
27) Sahlin L et al.:Impaired leukocyte influx in cervix of postterm women not responding to prostaglandin priming. Reprod Biol Endocrinol 6:36, 2008.
 
28) Kaga N, Katsuki Y. Obata M et al.:Repeated administration of low-dose lipopolysaccharide induces preterm delivery in mice. A model for human preterm parturition and for assessment of the therapeutic ability of drugs against preterm delivery. Am J Obstet Gynecol 174:754-9, 1996.
 
29) Kaga N, Katsuki Y, Futamura Y et al.:Role of urinary trypsin inhibitor in the maintenance of pregnancy in mice. Obstet Gynecol 88:872-82. 1996.
PubMed
30) Kaga N, Katsuki Y, Kajikawa S, et al. Preventive effect of ritodrine hydrochloride and/or urinary trypsin inhibitor against lipopolysaccharide-induced preterm delivery in mice. Acta Obstet Gynecol Scand 76:811-6, 1997.
PubMed
31) Machnicki M, Zimccki M, Zagulski T:Lactoferrin regulates the releasc of tumour necrosis factor alpha and interleukin-6 in vivo. Int J Exp Pathol 74:433-8, 1993.
 
32) Zhang GH, Mann DM, Tsai CM, Neutralization of endotoxin in vivo and in vivo by a human lactoferrin-derived peptide. Infect Immun 67:1353-8, 1999.
PubMed
33) Kanayama N, el Maradny E et al.:Urinary trypsin inhibitor suppresses premature cervical ripening. Eur J Obstet Gynecol Reprod Biol. 60:181-186, 1995.
PubMed

書評

最近チェックした商品履歴

Loading...